Cadila: Racing ahead - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Cadila: Racing ahead

Jul 9, 2002

A 16% rise in turnover reported by Cadila for FY02 is quite encouraging, especially considering the fact that the first half yearly growth was a mere 7%. On an annual basis, operating margins have also shown an improvement. The company has ambitious plans to emerge amongst the top 3 pharmaceutical companies in India by March 2004. Post the acquisition of controlling stake in German Remedies, the company is open to further in-organic growth.

(Rs m) FY01 FY02 Change
Sales 5,088 5,888 15.7%
Other Income 74 41 -44.1%
Expenditure 4,351 4,997 14.8%
Operating Profit (EBDIT) 737 891 20.9%
Operating Profit Margin (%) 14.5% 15.1%
Interest (46) 11 -123.8%
Depreciation 149 188 26.1%
Profit before Tax 708 734 3.6%
Tax 55 62 12.5%
Profit after Tax/(Loss) 653 672 2.9%
Net profit margin (%) 12.8% 11.4%  
No. of Shares (eoy) (m) 60 60  
Diluted Earnings per share* 10.9 11.2  
P/E (at current price) 12.1  

The strong growth rate in the last two quarters has been possible due to launch of new products in the neuroscience division, acquisition of perpetual rights to market five leading brands from Asta and acquisition of 'Aten' brand from Kopran last year. Further, the company has also logged several co-marketing alliances with Kopran, Ranbaxy and E-Merck. However, margins in this business are low compared to other businesses which partially explains the drop in overall margins.Realising its over dependence on few slow growing therapeutic segments, the company has made some rapid moves, including acquisitions, which will strongly position the company in some of the fast growing therapeutic segments. In its bid to further fuel in-organic growth, Cadila acquired the Vadodara-based Banyan Chemicals Ltd (BCL) for Rs 205 m.

The acquisition of BCL is expected to help the company in exploring export markets. BCL already has a US FDA approved unit for the manufacture of bulk drugs with export sales of Rs 250 m to Geneva Pharmaceuticals Technology Corporation of the US, a subsidiary of Novartis. The company plans to rapidly penetrate the export markets in the US through BCL. While the acquisition of BCL would give Cadila direct entry into the US bulk drug market, exports of formulations would take another two years, as the company is in the process of getting US FDA approval for the formulation plant. Cadila has plans to keep BCL as a separate subsidiary, though it may consider merging it with itself later.

It may be recalled that the company acquired a 27.7% stake in German Remedies for a consideration of Rs 1.5 bn last year. It also acquired perpetual rights to market five leading brands from Asta (one of the promoter of German Remedies). Post that the company did an open offer for the shareholders of German Remedies, taking the total stake in the company to 55.4%. The financing of the same would be done through a mix of debt (Rs 2,000 m) and internal accruals. The company has made a secondary open offer for German Remedies shareholders at a price of Rs 300/- per share for acquiring the remaining shareholding (45%) in GRL. In the event of the company's shareholding crossing 90% through the proposed open offer, it plans to seek the delisting of GRL.

Cadila-German Remedies: Merged Picture
Rs m Cadila German Remedies Merged Entity*
Net Sales 5,888 1,960 7,848
Operating Margins (%) 15.1% 19.1% 16.1%
Net Profit 672 249 921
EPS (Rs.) NA NA 15.4

The in-organic growth strategy of Cadila group has no doubt helped it to create a robust entity. However, what is concerning is the rising interest burden on the company. The debt figure has risen considerably in last one year to fund its acqusitions and research initiatives. The payback period of these acquisitions would have to justify the rise in interest costs. Further, the company has yet to prove its performance in the exports market. The valuations of the company going forward would thus depend on how fast the debt backed acquisitions of the company payoff. At the current market price of Rs 135, the stock trades at 9x its FY02 earnings on a consolidated basis.

Equitymaster requests your view! Post a comment on "Cadila: Racing ahead". Click here!


More Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 25, 2020 (Close)


  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks